[1]杨越茗,唐文熙,刘永军.药物经济学评价中患者用药依从性的识别、测量与估值[J].卫生经济研究,2021,38(11):18-21.
　YANG Yue-ming,TANG Wen-xi,LIU Yong-jun.Identification, Measurement and Evaluation of Patients' Drug Compliance in Pharmacoeconomic Evaluation[J].Journal Press of Health Economics Research,2021,38(11):18-21.
点击复制

药物经济学评价中患者用药依从性的识别、测量与估值
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年11期
页码:
18-21
栏目:
方法学应用
出版日期:
2021-10-29

文章信息/Info

Title:
Identification, Measurement and Evaluation of Patients' Drug Compliance in Pharmacoeconomic Evaluation
作者:
杨越茗1; 唐文熙1; 刘永军1
1.中国药科大学，江苏 南京 211198
Author(s):
YANG Yue-ming;  TANG Wen-xi;  LIU Yong-jun
China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
药物经济学; 依从性; 成本; 效果
Keywords:
pharmacoeconomic;  compliance;  cost;  effectiveness
分类号:
R95
文献标志码:
A
摘要:
分析患者用药依从性的定义与分类、指标与测量方法、对效果和成本的影响，讨论将依从性纳入药物经济学评价的方法和流程。结果显示：在药物经济学评价纳入依从性时，应明确依从性的定义；依从性对效果的影响复杂，在分析时可参考三个因素——患者不依从的形式、疾病的病理生理过程和药物代谢动力学特征；在考察依从性对成本的影响时，需结合临床效果的变化具体分析。
Abstract:
This paper analyzes the definition and classification, indicators and measurement methods of patients' drug compliance, and their effects on effectiveness and cost, and discuss the methods and processes of bringing compliance into pharmacoeconomic evaluation. The results show that when compliance is included in pharmacoeconomic evaluation, the definition of compliance should be clearly defined; and due to the influence of compliance on the effectiveness is complex, we can refer to three factors in the analysis - the form of patient non-compliance, the pathophysiological process of the disease and the characteristics of pharmacokinetics; when investigating the effect of compliance on cost, we need to analyze the changes of clinical effect.

参考文献/References:

[1] Burrell A,Wong P,Ollendorf D,et al.PHP46 DEFINING COMPLIANCE/ADHERENCE AND PERSISTENCE:ISPOR SPECIAL INTEREST WORKING GROUP[J].Value in Health,2005,8(6): A194-A5.
[2] Cutler R L,Fernandez-Llimos F,Frommer M,et al.Economic impact of medication non-adherence by disease groups:a systematic review[J].BMJ open,2018, 8(1):e016982.
[3] Urquhart J,De Klerk E.Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens [J].Statistics in medicine,1998,17(3):251-267.
[4] Hughes D A,Bagust A,Haycox A,et al.Accounting for noncompliance in pharmacoeconomic evaluations [J].PharmacoEconomics, 2001,19(12):1185-1197.
[5] DiMatteo M R.Variations in patients' adherence to medical recommendations:a quantitative review of 50 years of research[J].Medical care,2004, 42(3):200-209.
[6] Giannetti V J,Kamal K M.Adherence With Therapeutic Regimens:Behavioral and Pharmacoeconomic Perspectives[J].Journal of pharmacy practice,2016,29(2):138-143.
[7] Dodd S,White I R,Williamson P.Nonadherence to treatment protocol in published randomised controlled trials: a review[J].Trials, 2012,13(84).
[8] Miller G E,Sarpong E M,Hill S C.Does increased adherence to medications change health care financial burdens for adults with diabetes?[J].Journal of diabetes,2015,7(6):872-880.
[9] Cleemput I,Kesteloot K,DeGeest S.A review of the literature on the economics of noncompliance.Room for methodological improvement [J].Health policy (Amsterdam, Netherlands),2002,59(1):65-94.
[10] Hiligsmann M,Boonen A,Rabenda V,et al.The importance of integrating medication adherence into pharmacoeconomic analyses: the exam ple of osteoporosis [J].Expert review of pharmacoeconomics & outcomes research,2012,12(2):159-166.
[11] Rudd P,Byyny R L,Zachary V,et al.The natural history of medication compliance in a drug trial:limitations of pill counts[J].Clinical pharmacology and therapeutics,1989,46(2):169-176.
[12] Vrijens B,De Geest S,Hughes D A,et al.A new taxonomy for describing and defining adherence to medications[J].British journal of clinical pharmacology,2012,73(5):691-705.
[13] Zafari Z,Lynd L D,FitzGerald J M,et al.Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma:a simulation study[J].The Journal of allergy and clinical immunology,2014,134(4):908-915.
[14] Chongmelaxme B,Chaiyakunapruk N,Dilokthornsakul P.Incorporating adherence in cost-effectiveness analyses of asthma:a systematic review[J].Journal of medical economics,2019,22(6):554-566.
[15] Pennington M,McCrone P.Does Non-Adherence Increase Treatment Costs in Schizophrenia?[J].PharmacoEconomics,2018,36(8):941-955.
[16] Hughes D A,Bagust A,Haycox A,et al.The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature[J].Health economics,2001,10(7):601-615.
[17] Hughes D, Cowell W,Koncz T,et al.Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations[J].Value in health :the journal of the International Society for Pharmacoeconomics and Outcomes Research,2007,10(6): 498-509.
[18] Damen J,Thuresson P O,Heeg B,et al.A pharmacoeconomic analysis of compliance gains on antipsychotic medications[J].Applied health economics and health policy,2008,6(4):189-197.
[19] Slejko J F,Sullivan P W,Anderson H D,et al.Dynamic medication adherence modeling in primary prevention of cardiovascular disease:a Markov microsimulation methods application[J].Value in health:the journal of the International Society for Pharmacoeconomics and Outcomes Research,2014,17(6):725-731.
[20] Alshreef A,Latimer N,Tappenden P,et al.Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment:A Systematic Review of Methodological Papers [J].Medical decision making:an international journal of the Society for Medical Decision Making,2019,39(8):910-925.

相似文献/References:

[1]黄泽华,潘 越,钭江苑,等.药物经济学在医保决策中的应用[J].卫生经济研究,2017,(03):37.
[2]董心月,张伶俐,邵 蓉.英国价值定价理念与药品补偿制度的衔接及启示[J].卫生经济研究,2018,(10):54.
　DONG Xin-yue,ZHANG Ling-li,SHAO Rong.The Connection and Enlightenment of British Value Pricing Concept and Drug Compensation System[J].Journal Press of Health Economics Research,2018,(11):54.
[3]杜 怿,李 灿,方 刚,等.医保药物经济性评价质量评估量表研究及启示[J].卫生经济研究,2020,(06):28.
　DU Yi,LI Can,FANG Gang,et al.Research and Enlightenment of Quality Assessment Scale for Medical Insurance Drugs' Economic Evaluation[J].Journal Press of Health Economics Research,2020,(11):28.
[4]胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(01):9.
　HU Shanlian.Review and Prospects of Medical Insurance Price Negotiation in China[J].Journal Press of Health Economics Research,2024,41(11):9.

更新日期/Last Update: 2021-10-29